Gentian Diagnostics ASA (OSL:GENT)

Market Cap	875.99M
Revenue (ttm)	163.38M
Net Income (ttm)	42.19M
Shares Out	15.42M
EPS (ttm)	2.65
PE Ratio	21.47
Forward PE	35.24
Dividend	0.40 (0.71%)
Ex-Dividend Date	May 7, 2025

Volume	500
Average Volume	2,611
Open	56.40
Previous Close	56.40
Day's Range	56.40 - 56.40
52-Week Range	37.00 - 65.80
Beta	0.26
RSI	49.68
Earnings Date	Oct 23, 2025

About Gentian Diagnostics ASA

Gentian Diagnostics ASA develops, manufactures, and sells biochemical reagents for use in medical diagnostics and research in the United States, Asia, and Europe. The company offers in-vitro diagnostic reagents for clinical chemistry analyzers, such as Gentian Circulating Calprotectin Immunoassay, a turbidimetric assay used for the measurement of calprotectin in plasma and serum for detection and assessment of inflammation; Gentian Cystatin C Immunoassay test kit, a GFR marker for the diagnosis and therapeutic control of renal function and chro...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2001
• Employees: 63
• Stock Exchange: Oslo Børs
• Ticker Symbol: GENT